Investors

Press Releases

Date Title View
Toggle Summary Tetraphase Pharmaceuticals to Present Eravacycline and TP-6076 Data at ASM Microbe 2018
– Four Abstracts Selected for Poster Presentations – – Presentations Include New Eravacycline Pooled Analysis of IGNITE 1 and IGNITE4 and Data Highlighting the Pre-Clinical Activity of TP-6076 – WATERTOWN, Mass. , May 21, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc.
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present at the UBS Global Healthcare Conference
WATERTOWN, Mass. , May 09, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant infections, announced today that its corporate presentation will be webcast live at the UBS
View HTML
Toggle Summary Tetraphase Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Highlights
WATERTOWN, Mass. , May 03, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the first
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present Data at the 38th Annual Meeting of the Surgical Infection Society
WATERTOWN, Mass. , April 19, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced two data presentations at the
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present Data at 28th European Congress of Clinical Microbiology and Infectious Diseases
– Phase 3 IGNITE4 Results in Complicated Intra-Abdominal Infection Recognized as a ‘Best Rated Abstract’ – – Other Key Eravacycline and TP-6076 Data to Also be Highlighted – WATERTOWN, Mass. , April 12, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc.
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present at H.C. Wainwright Annual Global Life Sciences Conference
WATERTOWN, Mass. , April 02, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present at 17th Annual Needham Healthcare Conference
WATERTOWN, Mass. , March 20, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc . (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate
View HTML
Toggle Summary Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results, Highlights Achievements and Key 2018 Milestones
Achieved positive results of Eravacycline in Phase 3 IGNITE 4 clinical trial for cIAI  Filed NDA in US for IV Eravacycline for cIAI and PDUFA date is August 28 th Raised over $65 million through underwritten equity offering  2018 milestones include preparation for commercial launch of Eravacycline
View HTML
Toggle Summary Tetraphase Pharmaceuticals Appoints Larry Edwards Chief Operating Officer
WATERTOWN, Mass. , March 01, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced the promotion of Larry
View HTML
Toggle Summary Tetraphase Pharmaceuticals Announces FDA Acceptance for Filing of its NDA Submission for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections (cIAI)
PDUFA Date Set for August 28, 2018 WATERTOWN, Mass. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today
View HTML